AB Science announced new data reporting long-term survival analysis of masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis (ALS) have been…
MediWound announced positive topline results from its pivotal phase 3 pediatric clinical study (CIDS – Children Innovation Debridement Study) evaluating NexoBrid versus standard-of-care (SOC) in…
Gilead presented new results from the ongoing Phase 2/3 CAPELLA trial evaluating lenacapavir in heavily treatment-experienced people living with multi-drug resistant HIV. The findings demonstrate…
Alexion Pharmaceuticals announced positive topline results from a Phase 3 study evaluating the safety and efficacy of Ultomiris (ravulizumab-cwvz) in adults with generalized myasthenia gravis (gMG).…
Last month, the University of Louisville (UofL) reported on a breakthrough use of cell therapy, that is stem cells derived from a patient’s own bone…
Hepion Pharmaceuticals (formerly ContraVir Pharmaceuticals) reported topline results from its Phase 2a AMBITION clinical trial, evaluating CRV431 in patients with non-alcoholic steatohepatitis (NASH). All primary…
Affinivax and Astellas presented data from a phase 2 trial evaluating ASP3772, a vaccine developed using Affinivax’s proprietary MAPS (Multiple Antigen-Presenting System) platform technology and…
KalVista Pharmaceuticals presented phase 2 data for KVD900 in a late-breaking session at European Academy of Allergy and Clinical Immunology (EAACI) Congress. The placebo-controlled, double-blind cross-over trial, the…
ALX Oncology presented updated clinical data from its ongoing ASPEN-01 trial evaluating ALX148 in combination with trastuzumab and chemotherapy for the treatment of gastric or…
Incyte and Novartis announced that positive data from the Phase 3 REACH3 study have been published in The New England Journal of Medicine (NEJM). REACH3, sponsored…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
